SEC EDGARJUN 152 min read$CDNA

Hanna John Walter JR sold $528K of CDNA

Hanna John Walter JR (President and CEO) sold 21,998 shares of CareDx, Inc. (CDNA) at $24.02 ($0.53M total) on 2026-06-11 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Hanna John Walter JR

Published Jun 15, 2026, 9:06 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Jun 15, 2026, 9:09 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$CDNA

Neutral

medium confidence

Mentioned

$CDNA

Relevance

4/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$CDNANeutralLow

Why it matters

The CEO’s open-market sale totaling ~$528.4K is newly disclosed, but the presence of a pre-arranged 10b5-1 plan suggests reduced informational content.

Market read

This is a modest sentiment datapoint; it is unlikely to drive a durable repricing without additional fundamental news.

What to watch

Traders may over-weight insider sales; without accompanying changes in guidance, trials, or financing, the signal is typically weak.

Relevance 4/10Novelty 6/10Timing: Filed 2026-06-15; sale executed 2026-06-11.

Background

The article is an SEC Form 4 insider transaction disclosure for CareDx, Inc. (CDNA).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CDNANeutralMedium confidence

Context

CareDx CEO Hanna John Walter Jr sold 21,998 shares on 2026-06-11 for ~$528.4K under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction is more sentiment-driven than fundamental.

Evidence & confidence

The filing is a primary-source Form 4, but it specifies a pre-arranged 10b5-1 plan and provides no new operating/regulatory catalyst.

Market effects

Sector

No direct sector read-through; this is company-specific insider transaction disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity/compensation rather than bearish expectations.

Key entities

issuer
CareDx, Inc.
Company whose CEO insider sale is disclosed on SEC Form 4.
insider
Hanna John Walter Jr
President and CEO; sold 21,998 shares on 2026-06-11 under a 10b5-1 plan.

Read at source ← All news

AUG 12

$CDNAMed

Does CareDx’s Profit Jump And Higher 2026 Outlook Change The Bull Case For CDNA?

CareDx (CDNA) reported Q2 2026 revenue of $131.95M and net income of $110.64M, reversing a prior-year loss. It raised its full-year 2026 revenue outlook to $490–500M, completed a $50M buyback, and filed a $80.3M shelf for ESOP shares. The article links results to Medicare LCD frequency limits starting Aug. 30, 2026.

simplywall.st6 min

AUG 10

$CDNAMed

CareDx (CDNA) Trades 68% Above Fair Value Following Strong Q2 And Raised Guidance

CareDx (CDNA) reported Q2 2026 results showing a shift from a prior net loss to net income of $110.64 million, with higher year-over-year revenue and raised full-year guidance, according to the company. The article cites a sharp share-price rise and a fair value estimate of $28 versus a $47.07 close, implying overvaluation.

simplywall.st6 min

AUG 4

$CDNAMedAI 8/10

Why CareDx (CDNA) Is Up 33.8% After Strong Q2 Profit, Higher 2026 Outlook And ESOP Shelf

CareDx (CDNA) reported Q2 2026 revenue of $131.95M versus $86.68M a year earlier and net income of $110.64M versus a $8.57M loss. It raised its full-year 2026 revenue outlook to $490M to $500M and filed an $80.30M shelf for 2,267,800 shares tied to an ESOP.

simplywall.st4 min

AUG 1

$CDNAMedAI 8/10

CareDx Q2 Earnings Call Highlights

CareDx (NASDAQ:CDNA) provided Q2 earnings call guidance. Full-year testing volume is forecast at 258,000 to 266,000 tests and testing-services revenue around $400 million, including $24 million specialty oncology. Patient and digital revenue is expected at $72 million, lab products $23 million, and non-GAAP gross margin 71% to 73%. The company also discussed Medicare LCD coverage, Q3 and Q4 test assumptions, and pipeline updates for AlloHeme and HistoMap.

yahoo.com6 min

JUL 31

$CDNAHighAI 9/10

Why CareDx Stock Jumped Today

CareDx (CDNA) shares rose 14.72% after the company raised its full-year sales and earnings outlook. In Q2, revenue grew 52% to $132 million and adjusted net income rose to $20 million, or $0.37 per share. CareDx increased FY revenue guidance to $490M-$500M and EBITDA to $66M-$78M, citing demand and reimbursement coverage.

fool.com4 min

JUL 30

$CDNAHigh

CareDx, Inc. (CDNA): Results of Operations and Financial Condition

CareDx, Inc. (CDNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CareDx Announces Second Quarter 2026 Financial Results Second Quarter Revenue Growth of 52% to $132 Million Raises 2026 Revenue Guidance to $490 Million to $500 Million and Raises 2026 AEBITDA Guidance to $66 Million to $78 Million BRISBANE, Calif. — (BUSINESS WIRE)

SEC EDGAR 8-K4 min